Osteoartritte Biyokimyasal Belirteçler: Umut Vadeden Bir Aday Var mı?

Year 2016, Volume: 17 Issue: 1, 27 - 34, 01.04.2016

Elif Aydın Yasemin Turan

Abstract

Osteoartrit (OA) en sık rastlanan dejeneratif eklem hastalığıdır. OA her yıl milyonlarca kişiyi etkileyerek, geriatrik yaş grubunun en önemli ağrı sebebi haline gelmektedir. Eklem kıkırdağının ilerleyici hasarı hastalığın en belirgin özelliklerinden biridir. Hastalığın tanısı daha çok klinik ve radyolojik olarak konmaktadır, ancak bu yöntemler erken dönemdeki olguları saptamada ve hastalık son durumunu tahmin etmede yetersiz kalmaktadır. OA hastalarında erken tanı konabilmesi, hastalık aktivitesinin değerlendirilmesi ve tedaviye yanıtın izlenebilmesi için biyokimyasal belirteçlere ihtiyaç vardır. Bu alanda aday biyokimyasal belirteçlerin saptanabilmesi için son dönemde birçok çalışma yayınlanmıştır. Bu yazının amacı kıkırdak, sinovyum ve kemik döngüsünü yansıtan bu biyokimyasal belirteçlerin klinik kullanımları ile ilgili yapılan son dönem çalışmaların derlenmesidir

Keywords

Osteoartrit, biyobelirteçler, kemik, kıkırdak, sinovyum

Biochemical Markers for Osteoarthritis: Is There any Promising Candidate?

Abstract

Osteoarthritis (OA) is the most common degenerative joint disease. OA affects millions of individuals each year and becoming the most important cause of pain in geriatric population. Progressive destruction of articular cartilage is one of the prominent features of the disease. The diagnosis of OA is generally based on clinical and radiographical findings, which are insufficient to determine early-stage OA and predict disease course. There is a need for biomarkers that help clinicians early diagnose, assess disease activity, predict prognosis and monitor response to therapy. There are a growing number of publications regarding candidate markers in this field. The aim of this paper was to review recent studies on biochemical markers that reflect cartilage, synovial and bone turnover and their clinical use in patients with OA.

Keywords

Osteoarthritis, biomarkers, bone, cartilage, synovium

References

• 1. Vignon E, Garnero P, Delmas P, Avouac B, Bettica P, Boers M, et al; Respect of Ethics and Excellence in Science (GREES): Osteoarthritis Section. Recommendations for the registration of drugs used in the treatment of osteoarthritis: An update on biochemical markers. Osteoarthritis Cartilage 2001; 9: 289-93.
• 2. Garnero P. Use of biochemical markers to study and follow patients with osteoarthritis. Curr Rheumatol Rep 2006; 8: 37-44.
• 3. Lotz M, Martel-Pelletier J, Christiansen C, Brandi ML, Bruyere O, Chapurlat R, et al. Value of biomarkers in osteoarthritis: Current status and perspectives. Ann Rheum Dis 2013; 72: 1756-63.
• 4. Hedbom E, Antonsson P, Hjerpe A, Aeschlimann D, Paulsson M, Rosa-Pimentel E, et al. Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 1992; 267: 6132-6.
• 5. Wisłowska M, Jablonska B. Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis. Clin Rheumatol 2005; 24: 278-84.
• 6. Cauza E, Hanusch-Enserer U, Frischmuth K, Fabian B, Dunky A, Kostner K. Short-term infliximab therapy improves symptoms of psoriatic arthritis and decreases concentrations of cartilage oligomeric matrix protein. J Clin Pharm Ther 2006; 31: 149-52.
• 7. Bjørnhart B, Juul A, Nielsen S, Zak M, Svenningsen P, Müller K. Cartilage oligomeric matrix protein in patients with juvenile idiopathic arthritis: Relation to growth and disease activity. J Rheumatol 2009; 36: 1749-54.
• 8. Hoch JM, Mattacola CG, Medina McKeon JM, Howard JS, Lattermann C. Serum cartilage oligomeric matrix protein (sCOMP) is elevated in patients with knee osteoarthritis: A systematic review and meta-analysis. Osteoarthritis Cartilage 2011; 19: 1396-404.
• 9. Hunter DJ, Li J, LaValley M, Bauer DC, Nevitt M, DeGroot J, et al. Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: The boston osteoarthritis knee study. Arthritis Res Ther 2007; 9: R108.
• 10. Kumm J, Tamm A, Lintrop M, Tamm A. Association between ultrasonographic findings and bone/cartilage biomarkers in patients with early-stage knee osteoarthritis. Calcif Tissue Int 2009; 85: 514-22.
• 11. Kumm J, Tamm A, Lintrop M, Tamm A. The value of cartilage biomarkers in progressive knee osteoarthritis: Cross-sectional and 6-year follow-up study in middle-aged subjects. Rheumatol Int 2013; 33: 903-11.
• 12. Fernandes FA, Pucinelli ML, da Silva NP, Feldman D. Serum cartilage oligomeric matrix protein (COMP) levels in knee osteoarthritis in a Brazilian population: Clinical and radiological correlation. Scand J Rheumatol 2007; 36: 211-5.
• 13. Conrozier T, Saxne T, Fan CS, Mathieu P, Tron AM, Heinegard D, et al. Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: A one year prospective study. Ann Rheum Dis 1998; 57: 527-32.
• 14. Golightly YM, Marshall SW, Kraus VB, Renner JB, Villaveces A, Casteel C, et al. Biomarkers of incident radiographic knee osteoarthritis: Do they vary by chronic knee symptoms? Arthritis Rheum 2011; 63: 2276-83.
• 15. Verma P, Dalal K. Serum cartilage oligomeric matrix protein (COMP) in knee osteoarthritis: A novel diagnostic and prognostic biomarker. J Orthop Res 2013 ;31: 999-1006.
• 16. Lohmander LS, Saxne T, Heinegård DK. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann Rheum Dis 1994; 53: 8-13.
• 17. Dahlberg L, Roos H, Saxne T, Heinegård D, Lark MW, Hoerrner LA, Lohmander LS. Cartilage metabolism in the injured and uninjured knee of the same patient. Ann Rheum Dis 1994; 53: 823-7.
• 18. Jordan JM, Luta G, Stabler T, Renner JB, Dragomir AD, Vilim V, et al. Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: The Johnston County Osteoarthritis Project. Arthritis Rheum 2003; 48: 675-81.
• 19. Smith RK, Zunino L, Webbon PM, Heinegard D. The distribution of cartilage oligomeric matrix protein (COMP) in tendon and its variation with tendon site, age and load. Matrix Biol 1997; 16: 255-71.
• 20. Andersson ML, Thorstensson CA, Roos EM, Petersson IF, Heinegard D, Saxne T. Serum levels of cartilage oligomeric matrix protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis. BMC Musculoskelet Disord 2006; 7: 98.
• 21. Henrotin Y, Addison S, Kraus V, Deberg M. Type II collagen markers in osteoarthritis: What do they indicate? Curr Opin Rheumatol 2007;19: 444-50.
• 22. Garnero P, Conrozier T, Christgau S, Mathieu P, Delmas PD, Vignon E.Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis. Ann Rheum Dis 2003; 62: 939-43.
• 23. Garnero P, Charni N, Juillet F, Conrozier T, Vignon E. Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis. Ann Rheum Dis 2006; 65: 1639-44.
• 24. Charni N, Juillet F, Garnero P. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2005; 52: 1081-90.
• 25. Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, Uitterlinden AG, Pols HA. A new marker for osteoarthritis: Cross-sectional and longitudinal approach. Arthritis Rheum 2004; 50: 2471-8.
• 26. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001; 60: 619-26.
• 27. Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002; 46: 2613-24.
• 28. Sharif M, Kirwan J, Charni N, Sandell LJ, Whittles C, Garnero P. A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis- -association with disease progression. Rheumatology (Oxford) 2007; 46: 938-43.
• 29. van Spil WE, DeGroot J, Lems WF, Oostveen JC, Lafeber FP. Serum and urinary biochemical markers for knee and hip-osteoarthritis: A systematic review applying the consensus BIPED criteria. Osteoarthritis Cartilage 2010; 18: 605-12.
• 30. Mouritzen U, Christgau S, Lehmann HJ, Tanko LB, Christiansen C. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: Influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis 2003; 62: 332-6.
• 31. DeGroot J, Bank RA, Tchetverikov I, Verzijl N, TeKoppele JM. Molecular markers for osteoarthritis: The road ahead. Curr Opin Rheumatol 2002; 14: 585-9.
• 32. Rousseau JC, Zhu Y, Miossec P, Vignon E, Sandell LJ, Garnero P, et al. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2004; 12: 440-7.
• 33. Ishijima M, Watari T, Naito K, Kaneko H, Futami I, YoshimuraIshida K, et al. Relationships between biomarkers of cartilage, bone, synovial metabolism and knee pain provide insights into the origins of pain in early knee osteoarthritis. Arthritis Res Ther 2011; 13: R22.
• 34. Deberg MA, Labasse AH, Collette J, Seidel L, Reginster JY, Henrotin YE. One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cartilage 2005; 13: 1059-65.
• 35. Deberg M, Dubuc JE, Labasse A, Sanchez C, Quettier E, Bosseloir A, et al. One-year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement. Ann Rheum Dis 2008; 67: 168- 74.
• 36. Sugiyama S, Itokazu M, Suzuki Y, Shimizu K. Procollagen II C propeptide level in the synovial fluid as a predictor of radiographic progression in early knee osteoarthritis. Ann Rheum Dis 2003; 62: 27-32.
• 37. Jordan KM, Syddall HE, Garnero P, Gineyts E, Dennison EM, Sayer AA, et al. Urinary CTX-II and glucosyl-galactosylpyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men. Ann Rheum Dis 2006; 65: 871-7.
• 38. Gineyts E, Mo JA, Ko A, Henriksen DB, Curtis SP, Gertz BJ, et al. Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann Rheum Dis 2004; 63: 857-61.
• 39. Otterness IG, Weiner E, Swindell AC, Zimmerer RO, Ionescu M, Poole AR. An analysis of 14 molecular markers for monitoring osteoarthritis. Relationship of the markers to clinical endpoints. Osteoarthritis Cartilage 2001; 9: 224-31.
• 40. Thompson PW, Spector TD, James IT, Henderson E, Hart DJ. Urinary collagen crosslinks reflect the radiographic severity of knee osteoarthritis. Br J Rheumatol 1992; 31: 759-61.
• 41. Astbury C, Bird HA, McLaren AM, Robins SP. Urinary excretion of pyridinium crosslinks of collagen correlated with joint damage in arthritis. Br J Rheumatol 1994; 33: 11-5.
• 42. Campion GV, McCrae F, Schnitzer TJ, Lenz ME, Dieppe PA, Thonar EJ. Levels of keratan sulfate in the serum and synovial fluid of patients with osteoarthritis of the knee. Arthritis Rheum 1991; 34: 1254-9.
• 43. Poole AR, Ionescu M, Swan A, Dieppe PA. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis. J Clin Invest 1994; 94: 25-33.
• 44. Nakajima A, Nakagawa K, Aoki Y, Sonobe M, Shibata Y, Yamazaki M, et al. Changes in synovial fluid biochemical markers following arthroscopic surgery in patients with knee osteoarthritis. Rheumatol Int 2013; 33: 209-14.
• 45. Elliott AL, Kraus VB, Luta G, Stabler T, Renner JB, Woodard J, et al. Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis Rheum 2005; 52: 105-11.
• 46. Filkova M, Senolt L, Braun M, Hulejova H, Pavelkova A, Sleglova O, et al. Serum hyaluronic acid as a potential marker with a predictive value for further radiographic progression of hand osteoarthritis. Osteoarthritis Cartilage 2009; 17: 1615-9.
• 47. Pavelka K, Forejtova S, Olejarova M, Gatterova J, Senolt L, Spacek P, et al. Hyaluronic acid levels may have predictive value for the progression of knee osteoarthritis. Osteoarthritis Cartilage 2004; 12: 277-83.
• 48. Turan Y, Bal S, Gurgan A, Topac H, Koseoglu M. Serum hyaluronan levels in patients with knee osteoarthritis. Clin Rheumatol 2007; 26: 1293-8.
• 49. Manicourt DH, Fujimoto N, Obata K, Thonar EJ. Serum levels of collagenase, stromelysin-1, and TIMP-1. Age- and sexrelated differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis. Arthritis Rheum 1994; 37: 1774-83.
• 50. Manicourt DH, Bevilacqua M, Righini V, Famaey JP, Devogelaer JP. Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis. Drugs R D 2005; 6: 261-71.
• 51. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling.Trends Genet 1990; 6: 121-5.
• 52. Chevalier X, Conrozier T, Gehrmann M, Claudepierre P, Mathieu P, Unger S, et al. Tissue inhibitor of metalloprotease-1 (TIMP- 1) serum level may predict progression of hip osteoarthritis. Osteoarthritis Cartilage 2001; 9: 300-7.
• 53. Huang K, Wu LD. YKL-40: A potential biomarker for osteoarthritis. J Int Med Res 2009; 37: 18-24.
• 54. Zivanović S, Rackov LP, Vojvodić D, Vucetić D. Human cartilage glycoprotein 39 biomarker of joint damage in knee osteoarthritis. Int Orthop 2009; 33: 1165-70.
• 55. Kalichman L, Kobyliansky E. Radiographic hand osteoarthritis and serum levels of osteocalcin: Cross-sectional study. Rheumatol Int 2010; 30: 1131-5.
• 56. Bruyere O, Collette JH, Ethgen O, Rovati LC, Giacovelli G, Henrotin YE, et al. Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis. J Rheumatol 2003; 30: 1043-50.
• 57. Wang Y, Ebeling PR, Hanna F, O’Sullivan R, Cicuttini FM. Relationship between bone markers and knee cartilage volume in healthy men. J Rheumatol 2005; 32: 2200-4.
• 58. Naito K, Watari T, Obayashi O, Katsube S, Nagaoka I, Kaneko K. Relationship between serum undercarboxylated osteocalcin and hyaluronan levels in patients with bilateral knee osteoarthritis. Int J Mol Med 2012; 29: 756-60.
• 59. Jung YO, Do JH, Kang HJ, Yoo SA, Yoon CH, Kim HA, et al. Correlation of sonographic severity with biochemical markers of synovium and cartilage in knee osteoarthritis patients. Clin Exp Rheumatol 2006; 24: 253-9.
• 60. Pelletier JP, Raynauld JP, Caron J, Mineau F, Abram F, Dorais M, et al. Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis. Ann Rheum Dis 2010; 69: 2095-101.
• 61. Smith JW, Martins TB, Gopez E, Johnson T, Hill HR, Rosenberg TD. Significance of C-reactive protein in osteoarthritis and total knee arthroplasty outcomes. Ther Adv Musculoskelet Dis 2012; 4: 315-25.
• 62. Fahlgren A, Andersson B, Messner K. TGF-beta1 as a prognostic factor in the process of early osteoarthrosis in the rabbit knee. Osteoarthritis Cartilage 2001; 9: 195-202.
• 63. Ku JH, Lee CK, Joo BS, An BM, Choi SH, Wang TH, et al. Correlation of synovial fluid leptin concentrations with the severity of osteoarthritis. Clin Rheumatol 2009; 28: 1431-5.
• 64. Jiang L, Bao J, Zhou X, Xiong Y, Wu L. Increased serum levels and chondrocyte expression of nesfatin-1 in patients with osteoarthritis and its relation with BMI, hsCRP, and IL-18. Mediators Inflamm 2013; 2013: 631251.
• 65. Staikos C, Ververidis A, Drosos G, Manolopoulos VG, Verettas DA, Tavridou A. The association of adipokine levels in plasma and synovial fluid with the severity of knee osteoarthritis. Rheumatology (Oxford) 2013; 52: 1077-83.
• 66. Koskinen A, Juslin S, Nieminen R, Moilanen T, Vuolteenaho K, Moilanen E. Adiponectin associates with markers of cartilage degradation in osteoarthritis and induces production of proinflammatory and catabolic factors through mitogenactivated protein kinase pathways. Arthritis Res Ther 2011; 13: R184.